Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

CD19 Protein (AA 20-291) (His tag,FITC)

CD19 Origin: Human Host: HEK-293 Cells Recombinant > 95 % as determined by Tris-Bis PAGE,> 95 % as determined by HPLC
Catalog No. ABIN7274067
  • Target See all CD19 Proteins
    CD19 (CD19 Molecule (CD19))
    Protein Type
    Recombinant
    Protein Characteristics
    AA 20-291
    Origin
    • 30
    • 6
    • 4
    • 3
    • 3
    • 1
    • 1
    • 1
    Human
    Source
    • 25
    • 6
    • 5
    • 3
    • 3
    • 1
    • 1
    HEK-293 Cells
    Purification tag / Conjugate
    This CD19 protein is labelled with His tag,FITC.
    Purpose
    FITC-Compatible Human CD19 Protein
    Sequence
    Pro20-Lys291
    Characteristics
    FITC-Compatible Human CD19 Protein is expressed from HEK293 with His tag at the C-Terminus.It contains Pro20-Lys291.
    Purity
    > 95 % as determined by Tris-Bis PAGE,> 95 % as determined by HPLC
    Sterility
    0.22 μm filtered
    Endotoxin Level
    Less than 1EU per μg by the LAL method.
  • Restrictions
    For Research Use only
  • Format
    Liquid
    Buffer
    Supplied as 0.22 μm filtered solution in PBS ( pH 7.4).
    Storage
    -80 °C
    Storage Comment
    Valid for 12 months from date of receipt when stored at -80°C., Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
    Expiry Date
    12 months
  • Target
    CD19 (CD19 Molecule (CD19))
    Alternative Name
    CD19 (CD19 Products)
    Synonyms
    B4 Protein, CVID3 Protein, AW495831 Protein, CD19 Protein, CD19 molecule Protein, CD19 antigen Protein, CD19 Protein, Cd19 Protein
    Background
    CD19 is a B-lineage-specific transmembrane glycoprotein, the expression of which is maintained on more than 95 % B-cell malignancies. This strict lineage restriction makes CD19 an ideal target for immune therapies using chimeric antigen receptors (CARs). T cells engineered to express a chimeric antigen receptor (CAR) against CD19 have recently been FDA approved for the treatment of relapsed or refractory large B-cell lymphoma. Despite the success and curative potential of CD19 CAR T cells, several reports describing disease relapse due to antigen loss are now emerging.
    Molecular Weight
    60.1 kDa. Due to glycosylation, the protein migrates to 68-72 kDa based on Tris-Bis PAGE result.
    Pathways
    Fc-epsilon Receptor Signaling Pathway, EGFR Signaling Pathway, Neurotrophin Signaling Pathway
You are here: